No Data
Do Its Financials Have Any Role To Play In Driving Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Stock Up Recently?
Hengrui Pharmaceutical: Hengrui Pharmaceutical Report for the First Quarter of 2025
Hengrui Pharmaceutical\'s 2025 First Quarter Report
Jiangsu Hengrui Pharmaceuticals: Authorized revenue becomes the "accelerator" for performance.
Personnel, products, and research and development are gradually becoming Global.
Jiangsu Hengrui Pharmaceuticals (600276.SH) released its first-quarter performance, with a net income of 1.874 billion yuan, an increase of 36.9% year-on-year.
Jiangsu Hengrui Pharmaceuticals (600276.SH) released the first quarter report for 2025, with the company's first quarter revenue at 72...
The upfront payment for the new ADC drug has boosted revenue, Jiangsu Hengrui Pharmaceuticals' Q1 revenue increased by 20.14% year-on-year, and net income increased by 36.9% | Earnings Reports insights.
In Q1, Jiangsu Hengrui Pharmaceuticals' revenue increased by 20.14% year-on-year, net income attributable to the parent company increased by 36.9%, and net income after deductions increased by 29.35% year-on-year. The significant increase in net income was primarily due to the company receiving a $75 million upfront payment for external licensing.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
